openPR Logo
Press release

Radiopharmaceutical Market is Expected to Represent US$ 7.4 Bn by 2024

03-13-2018 02:52 PM CET | Health & Medicine

Press release from: Transparency Market Research

/ PR Agency: Transparency Market Research
Radiopharmaceutical Market is Expected to Represent US$ 7.4 Bn

Radiopharmaceutical Market: Snapshot

The global market for radiopharmaceuticals is poised for steady growth in the coming years, driven primarily by the rising use of radioisotopes for the treatment of various diseases, such as cancer, bone palliation, neurological disorders, and cardiovascular diseases. Around 35 million patients undergo treatment procedures for these diseases each year and this will continue to boost the demand for radiopharmaceuticals.

According to the Nuclear Energy Institute, radioisotopes are essential for biomedical research in order to cure AIDS, cancer, and Alzheimer’s disease. The World Nuclear Association states that around 10,000 hospitals across the world use radioisotopes in medicines and 90% of this is dedicated toward disease diagnosis.

The global radiopharmaceutical market was valued at US$4.7 bn in 2015 and is estimated to reach US$7.4 bn by 2024, expanding at a CAGR of 5.3% from 2016 to 2024.

Request Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=213
Growing Incidence of Cancer Driving Demand for Most Radioisotopes

Based on radioisotope, the technetium-99 segment led the global radiopharmaceuticals market, accounting for a share of 50.3% in 2015. This can be attributed to the high availability of technetium-99 from molybdenum-99, which is generated through the decay of uranium radioactive raw material inside the sources.

The 18F radioisotope segment is expected to gain market share during the forecast period due to the increase in demand for cyclotron-based radioisotopes for nuclear medicine and the advancement of technological systems such as PET and SPECT. The demand for other radioisotopes such as lutetium-177, rubidium-87, and gallium-62 is also high due to the rising demand for radioisotopes for cancer treatment, the surge in the prevalence of cardiovascular diseases, and the detection of other infectious diseases. Based on application, oncology took the lead owing to the growing use of various radioisotopes in the treatment of different cancers.

Radiopharmaceutical products are used by various end users such as hospitals, ambulatory surgical centers, and diagnostic centers. Hospitals formed the leading segment of the market in terms of revenue in 2015 due to the growing usage of radiopharmaceutical. This can be attributed to technological advancements in various systems to cure cancer patients and the rise in favorable government reimbursement policies to help patients recover their costs and provide precaution against biohazards. The ambulatory surgical centers and diagnostic centers segments are expected to gain market share by 2024 due to the introduction of advanced imaging technologies such as SPECT and PET.

Request Sample of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=213
Developing Regions to Witness Steady Growth despite Small Share in Global Market

The global radiopharmaceuticals market has been segmented into North America, Latin America, Asia Pacific, Europe, and the Middle East and Africa. North America led the radiopharmaceuticals market in 2015 in terms of revenue, with the U.S. emerging as the most prominent contributor to the radiopharmaceuticals market in North America. This can be attributed to the existence of several large nuclear reactors such as NRU, which accounts for a 30% to 40% share in the Mo-99 supply for the global production of nuclear medicine.

Europe is also expected to account for a significant share by 2024 due to the increase in the number of cyclotron installations for the production of radioisotopes used in the treatment of cancer and other diseases.

The Middle East and Africa is projected to account for a small share in the global market by 2024. However, growth in this market is likely to be attributed to the introduction of cyclotrons by the IBA Group and the setting up of new nuclear reactors such as ETRR-2 in South Africa for the production of radioisotopes.

Enquiry for discount on this report – https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=213
Latin America is estimated to account for a meager share by the end of the forecast period. However, it continues to be driven by the increase in domestic collaborations with foreign radiopharmaceutical companies and major suppliers of radioactive raw materials and the establishment of hospitals and ambulatory surgical centers for cancer patients.

Prominent players operating in the radiopharmaceutical market include Advanced Accelerator Applications (AAA), Eckert & Ziegler, GE Healthcare, IBA Radiopharma Solutions, Lantheus Holdings, Inc., Mallinckrodt plc., Nordion, Inc., Siemens Healthineers, and Positron Corporation.

Report Overview : https://www.transparencymarketresearch.com/radiopharmaceuticals-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Radiopharmaceutical Market is Expected to Represent US$ 7.4 Bn by 2024 here

News-ID: 976941 • Views:

More Releases from Transparency Market Research

Global SiC Ceramics Market Poised for Robust Growth, Projected to Reach USD 3.1 Billion by 2035 | Transparency Market Research
Global SiC Ceramics Market Poised for Robust Growth, Projected to Reach USD 3.1 …
The global silicon carbide (SiC) ceramics market continues to demonstrate strong growth potential, underpinned by accelerating demand from advanced industrial and electronic applications. Valued at US$ 1.8 Billion in 2024, the market is projected to reach US$ 3.1 Billion by 2035, expanding at a compound annual growth rate (CAGR) of 5.2% during the forecast period from 2025 to 2035. This steady expansion reflects the increasing importance of SiC ceramics as
Furfuryl Alcohol Market to Reach USD 1.34 Billion by 2035, Supported by Rising Demand for Bio-Based Chemicals and Expanding Foundry Industry | TMR
Furfuryl Alcohol Market to Reach USD 1.34 Billion by 2035, Supported by Rising D …
The global Furfuryl Alcohol Market was valued at US$ 624.3 million in 2024 and is projected to reach US$ 1,341.2 million by 2035, expanding at a compound annual growth rate (CAGR) of 7.2% from 2025 to 2035. This growth is primarily driven by the rising demand for bio-based and sustainable chemicals, along with the steady expansion of the foundry and metal casting industry, particularly across emerging economies in Asia Pacific. Gain a
Air-Entraining Agents Market Outlook 2035: Forecast to Reach US$ 2.48 Billion by 2035 at a CAGR of 3.5% Driven by Infrastructure Expansion and Climate-Resilient Concrete Demand
Air-Entraining Agents Market Outlook 2035: Forecast to Reach US$ 2.48 Billion by …
The global Air-Entraining Agents (AEAs) Market was valued at US$ 1.70 billion in 2024 and is projected to reach US$ 2.48 billion by 2035, expanding at a compound annual growth rate (CAGR) of 3.5% from 2025 to 2035. This steady growth trajectory reflects the essential role AEAs play in modern concrete formulations, particularly in infrastructure projects that demand long-term durability, freeze-thaw resistance, and improved workability. Despite being a mature segment within
A2P SMS Market Outlook 2035: Expanding from US$ 71.2 Bn in 2024 to US$ 117.0 Bn by 2035 at a CAGR of 4.2%
A2P SMS Market Outlook 2035: Expanding from US$ 71.2 Bn in 2024 to US$ 117.0 Bn …
The global Application-to-Person (A2P) SMS market is entering a phase of steady and resilient expansion, driven by the growing need for secure, reliable, and real-time communication between enterprises and consumers. Valued at US$ 71.2 Bn in 2024, the market is projected to reach US$ 117.0 Bn by 2035, expanding at a CAGR of 4.2% from 2025 to 2035. Despite the rise of internet-based messaging platforms, A2P SMS continues to maintain

All 5 Releases


More Releases for Radiopharma

Nuclear Pharmacy Market Future Business Opportunities 2025-2032 | Curium Pharma, …
The Latest study titled Nuclear Pharmacy Market 2025, published by Coherent Market Insights, provides valuable insights into both regional and global markets projected to grow in value from 2025 to 2032. The comprehensive research delves into the evolving market dynamics, value chain analysis, prominent investment areas, competitive landscape, regional outlook, and key market segments. It also offers a thorough assessment of the global market's drivers and constraints. Additionally, the report
Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and St …
Actinium's Chief Medical Officer, said, "In addition to demonstrating unprecedented 100% access to BMT in Iomab-B treated patients with active r/r AML and achieving the primary endpoint of dCR with high statistical significance, we are excited by the compelling outcomes in patients with a TP53 mutation in the SIERRA trial. We look forward to returning to EBMT and once again highlighting the positive results from the Phase 3 SIERRA trial
Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma A …
Biotech Stocks Taking Centerstage As the pharmaceutical industry ventures deeper into the era of precision medicine, radiopharmaceuticals, particularly those involving alpha emitters like Actinium-225 (Ac-225), are gaining prominence for their targeted approach to cancer treatment. Amid this innovative surge, Actinium Pharmaceuticals (NYSE:ATNM) emerges not just as a company with a promising pipeline but as a beacon of cutting-edge manufacturing capabilities that could very well position it as a prime buyout candidate
2030 Projections: Radiopharmaceutical Synthesizers Market to Deliver Dynamic Pro …
The Radiopharmaceutical Synthesizers Market Research Report 2023-2030 provides in-depth information on market trends, market capacity, industry size, growth factors, share, innovations, competitive environment, business problems, and more. This report's historical data confirms demand growth on a global, national, and regional scale. The studies on the global industry cover everything from comprehensive research to market size and forecasting to dynamics, growth factors, prospects, and hazards, as well as vendor knowledge. The
Automated Radiosynthesis Modules Market Strategic Assessment & SWOT Analysis 202 …
An Informative report titled as Global Automated Radiosynthesis Modules Market has recently been published by Report Consultant to its online repository. This statistical data offers an in-depth analysis by considering several segments, such as type, size, technology and applications. Different exploratory techniques such as, qualitative and quantitative analysis have been used to give data accurately. For better understanding of the customers, it uses effective graphical presentation techniques, such as graphs,
Cyclotron Market Growth Opportunities Analysis Report | GE Healthcare, Siemens H …
Cyclotron Market: Introduction According to the report, the global cyclotron market was valued at US$ 215.5 Mn in 2019. It is projected to expand at a CAGR of ~3% from 2020 to 2030. Expansion activities of key radiopharma players; applications in clinical trials; increase in the geriatric population; pipeline assessment of new drugs; and disease indication mortality are major factors driving the cyclotron market. The shutdown of a few nuclear reactors has led to the